

Contents

Preface to the Second Edition	ix
Preface to the First Edition	xi
Acknowledgments	xiii
List of Abbreviations	xv
List of Case Studies	xvii

Color Plates *follow p. 174*

Chapter 1 Approach to flow cytometry: General considerations

1.1	Reasons for the necessity of proper data analysis	2
1.1.1	The pitfalls of the FCM data format of “percent positive” per antibody tested	2
1.2	General aspects of FCM data analysis and interpretation	4
1.3	Other applications of FCM in hematopathology	7
1.4	Maturation and differentiation of hematopoietic elements: An overview based on the immunologic markers currently in use in the FCM laboratory	9

Chapter 2 FCM immunophenotyping and DNA analysis: Practical aspects that can affect data analysis and interpretation

2.1	Sample selection	13
2.1.1	Liquid specimens	14
2.1.2	Solid tissue specimens	15
2.2	Preparing nucleated cell suspensions	16
2.3	Cell yield and viability	16
2.4	Sample staining	16
2.4.1	Surface antigens	17
2.4.2	Intracellular antigens	17
2.4.3	DNA content	18
2.5	Data acquisition	19
2.5.1	Calibration	19
2.5.2	Color compensation	19
2.5.3	List mode data collection	20
2.5.4	Exclusion of nonviable cells	21
2.6	Antibody panel design	22
2.6.1	Antibody selection	23
2.6.1.1	Anti-light chain antibodies	23
2.6.2	Fluorochrome conjugation	26

2.7	Comprehensive antibody panels	31
2.7.1	Disease-oriented antibody panels	31
2.7.2	Antibody panels oriented by specimen type	32
2.8	Tailored panels and add-on testing	34
2.8.1	Minimal residual disease	36
2.9	FCM immunophenotyping data representation	37
2.9.1	Analysis panels	37
2.9.2	Color display	38
2.10	Approach to DNA data analysis	41
2.10.1	DNA ploidy	42
2.10.2	S-phase	42

Chapter 3 FCM data analysis on nearly homogeneous samples

3.1	FCM parameters	50
3.1.1	Forward scatter	50
3.1.2	Side scatter	53
3.1.3	Fluorescence	54
3.1.3.1	Heterogeneous fluorescence intensity (bimodal, variable)	64
3.2	Fluorescence dynamic range	71
3.3	Strategy to the visual review of FCM immunophenotyping data	71
3.4	Common SSC/CD45 patterns	73
3.4.1	Assessment of the blast population	73
3.4.2	Immature neoplastic cells with downregulated CD45	81
3.4.3	SSC/CD45 in mature lymphoid disorders	83
3.5	Other dot plot patterns useful in acute leukemia diagnosis	86
3.5.1	Useful antigenic features in AML	86
3.5.1.1	Myeloid phenotypic abnormalities and MRD detection	95
3.5.2	Precursor B-ALL versus bone marrow B-cell progenitors	98
3.5.3	Useful antigenic features in precursor T-lymphoma/leukemia	99
3.6	Evaluation of mature lymphoid malignancies	106
3.6.1	Assessment of surface light chain expression	106
3.6.2	Assessment of pan B-cell antigens	108
3.6.3	Useful antigenic features in mature B-cell malignancies	112
3.6.3.1	CD10 expression: Follicular center cell lymphomas	112
3.6.3.2	Pattern of CD20 and CD11c coexpression	117
3.6.3.3	CD5 expression	123
3.6.3.4	Aberrant B-cell profile	126
3.6.4	Identification of abnormal mature T-cells	131
3.6.5	Useful antigenic features in mature T-cell malignancies	150
3.7	Assessing the biological behavior of mature lymphoid neoplasms	166
3.8	Dot plot patterns in histiocytic proliferations and nonhematopoietic malignancies	171

Chapter 4 FCM data analysis on heterogeneous specimens

4.1	Identifying normal FCM samples	175
4.1.1	Benign/reactive solid lymphoid tissue (e.g., lymph nodes, tonsils)	175

4.1.1.1	Pattern of CD10/CD20 coexpression: Distinction between FRFH and FCC lymphoma	179
4.1.2	Normal peripheral blood and normal bone marrow	187
4.1.2.1	Blast region	190
4.1.2.2	Bone marrow B-cell precursors	192
4.1.2.3	Lymphocytes	192
4.1.2.4	Monocytes	208
4.1.2.5	Plasma cells	209
4.1.2.6	Erythroid precursors	213
4.1.2.7	Maturing myeloid cells	216
4.2	Abnormal heterogeneous samples with a detectable immature neoplastic population	220
4.2.1	Blasts of lymphoid lineage	221
4.2.2	Blasts of myeloid lineage	222
4.2.2.1	AML	224
4.2.2.2	High-grade MDS and MPD with increased blasts	226
4.3	Minimal residual disease	233
4.4	Abnormal heterogeneous samples with detectable mature neoplastic populations	233
4.4.1	Abnormal mature B-cells	238
4.4.1.1	Evaluation of CD5 and CD23	238
4.4.1.2	FCM features suggestive of anti-CD20 therapy	242
4.4.2	Abnormal mature T-cells and NK cells	245
4.4.3	Abnormal plasma cells present	255
4.5	Abnormal blood or bone marrow samples with no detectable neoplastic cells	260
4.5.1	Altered cellular composition and abnormal SSC	262
4.5.1.1	Increased monocytic elements	262
4.5.1.2	Increased eosinophils	262
4.5.1.3	Conspicuous basophils or mast cells	265
4.5.1.4	Abnormal SSC in granulocytes	265
4.5.2	Abnormal antigenic maturation in myeloid or erythroid precursors	273
4.5.2.1	Antigenic abnormalities in myeloid precursors	273
4.5.2.2	Antigenic abnormalities in erythroid precursors	280
4.5.2.3	Identifying low-grade MDS	280
4.6	Coexisting malignancies	285

Chapter 5 FCM interpretation and reporting

5.1	Immature hematopoietic malignancies	289
5.1.1	ALL/lymphoblastic lymphoma	290
5.1.2	Myeloid malignancies	292
5.1.2.1	AML-M3	292
5.1.2.2	AML with minimal maturation	292
5.1.2.3	AML with maturation	292
5.1.2.4	AML with monocytic differentiation	294
5.1.2.5	AML with erythroid hyperplasia	295
5.1.2.6	AML with megakaryocytic differentiation	295
5.1.2.7	MPD and MDS	295

5.1.3	Acute leukemias with a multilineage antigenic profile	300
5.2	Mature lymphoid malignancies	301
5.2.1	B-cell LPD/NHL	302
5.2.1.1	CD10 expression	302
5.2.1.2	Coexpression of CD11c, CD25 and CD103	306
5.2.1.3	Coexpression of CD5 and CD23	306
5.2.1.4	CD5 ⁺ CD23 ⁻ B-cell neoplasms	307
5.2.1.5	CD45 and/or pan B-cell antigens markedly downregulated	310
5.2.1.6	Nondescript B-cell phenotype and high FSC	311
5.2.1.7	Nondescript B-cell phenotype and low FSC	314
5.2.1.8	Monoclonal B-cells of undetermined significance	318
5.2.2	Plasma cell dyscrasias	318
5.2.3	T-cell LPD/NHL	320
5.2.3.1	CD4 ⁺ T-cell LPD/NHL	321
5.2.3.2	CD8 ⁺ disorders	323
5.2.3.3	CD30 ⁺ lymphoma	329
5.3	FCM reporting	333
	Suggested reading	335
	Appendix: Using the case studies CD-ROM	341
	Index	343